Sphinganine 1-phosphate, also known as D-erythro-Dihydrosphingosine 1-phosphate, is a polar sphingolipid metabolite. It plays a crucial role in regulating various cellular processes including cell migration, differentiation, survival, and complex physiological processes.

Sphinganine 1-phosphate (S1P) is a potent signaling molecule involved in cell stress responses, cancer, angiogenesis and lymphocyte trafficking. Sphinganine 1-phosphate functions primarily by activating a subgroup of the endothelial differentiation gene (EDG) family of G-protein coupled cell surface receptors. Sphinganine 1-phosphate has opposite effects in the regulation of cell metabolism. Sphinganine 1-phosphate regulates skeletal muscle differentiation and regeneration[1]. Sphinganine 1-phosphate (S1P) is involved in cancer. Sphinganine 1-phosphate regulates processes such as inflammation, which can drive tumorigenesis; neovascularization, which provides cancer cells with nutrients and oxygen; and cell growth and survival[1]. Sphinganine-1-Phosphate (1?μM) phosphorylates ERK MAPK, Akt, and HSP27 and induces HSP27 in human renal endothelial cells[2]. Cell Viability Assay[2]Cell Line: Human renal endothelial cells or human kidney proximal tubule (HK-2) cells Concentration: 1?μM Incubation Time: 2 or 4?hours Result: Induced HSP27 mRNA in cultured human renal endothelial cells. Phosphorylated ERK MAPK and AKT in human renal endothelial cells in a time-dependent manner. Phosphorylated and induced HSP27.

Sphinganine 1-phosphate can enhance wound healing in diabetic mice[1].

Sphinganine 1-phosphate provides renal and hepatic protection after liver ischemia and reperfusion (IR) injury in mice through selective activation of S1P1 receptors and pertussis toxin-sensitive G-proteins with subsequent activation of ERK and Akt. Sphinganine 1-phosphate (administered 0.1?mg/kg i.v. immediately before reperfusion and 0.2?mg/kg s.c. 2?h after reperfusion) protects against hepatic and renal injury after liver IR[2]. Animal Model: Male C57BL/6 mice (20-25?g)[2]Dosage: 0.1?mg/kg Administration: Administered i.v. immediately before reperfusion and 0.2?mg/kg s.c. 2 h after reperfusion Result: The plasma level of alanine aminotransferase (ALT) and Creatinine (Cr) was 80±6 U/L and 0.46±0.05 mg/dL, respectively. The increases in ALT (7474±557?U/L) and Cr (0.55±0.05?mg/dL) were significantly suppressed at 24?h after reperfusion in mice treated with 0.1?mg/kg i.v. before reperfusion and 0.2?mg/kg s.c. 2?h after reperfusion.